NCT04657991 2026-03-02
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03235245 2025-08-01
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT04074096 2024-06-03
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT05270044 2023-11-22
COLUMBUS-AD
Pierre Fabre Medicament
Phase 3 Active not recruiting